220355-63-5
Chemical Structure
UKI-1
Synonym(s): WX-UK1; UKI-1C
- CAS No.: 220355-63-5
- Formula:C32H47N5O5S
- Molecular Weight:613.81
IUPAC Name: ethyl (S)-4-(3-(3-carbamimidoylphenyl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate
InChIKey: ISJSHQTWOHGCMM-NDEPHWFRSA-N
SMILES: O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(N)=N)=C3)=O)CC1)OCC
Biological Activity: UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
UKI-1 | 96.13% | UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UKI-1-d8 acetate | UKI-1-d8 acetate (WX-UK1-d8 acetate) is the deuterium labeled UKI-1 acetate. UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. [Content Brief]
- [2]. Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301(2):465-75. [Content Brief]
